Genomic characterization of upper-tract urothelial carcinoma in patients with Lynch syndrome

Timothy F. Donahue, Aditya Bagrodia, François Audenet, Mark T.A. Donoghue, Eugene K. Cha, John P. Sfakianos, Dahlia Sperling, Hikmat Al-Ahmadie, Mark Clendenning, Christophe Rosty, Daniel D. Buchanan, Mark Jenkins, John Hopper, Ingrid Winship, Allyson S. Templeton, Michael F. Walsh, Zsofia K. Stadler, Gopa Iyer, Barry Taylor, Jonathan ColemanNoralane M. Lindor, David B. Solit, Bernard H. Bochner

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose Patients with Lynch syndrome (LS) have a significantly increased risk of developing upper-tract urothelial carcinoma (UTUC). Here, we sought to identify differences in the patterns of mutational changes in LS-associated versus sporadic UTUCs. Patients and Methods We performed targeted sequencing of 17 UTUCs from patients with documented LS-associated germline mutations (LS-UTUCs) using the Memorial Sloan Kettering Integrated Molecular Profiling of Actionable Cancer Targets targeted exon capture assay and compared the results with those from a recently characterized cohort of 82 patients with sporadic UTUC. Results Patients with LS-UTUC were significantly younger, had had less exposure to tobacco, and more often presented with a ureteral primary site compared with patients with sporadic UTUC. The median number of mutations per tumor was significantly greater in LS-UTUC tumors than in tumors from the sporadic cohort (58; interquartile range [IQR], 47-101 v 6; IQR, 4-10; P < .001), as was the MSIsensor score (median, 25.1; IQR, 17.9-31.2 v 0.03; IQR, 0-0.44; P < .001). Differences in the genetic landscape were observed between sporadic and LS-associated tumors. Alterations in KMT2D, CREBBP, or ARID1A or in DNA damage response and repair genes were present at a significantly higher frequency in LS-UTUC. CIC, NOTCH1, NOTCH3, RB1, and CDKN1B alterations were almost exclusive to LS-UTUC. Although FGFR3 mutations were identified in both cohorts, the R248C hotspot mutation was highly enriched in LS-UTUC. Conclusion LS-and sporadic UTUCs have overlapping but distinct genetic signatures. LS-UTUC is associated with hypermutation and a significantly higher prevalence of FGFR3 R248C mutation. Prospective molecular characterization of patients to identify those with LS-UTUC may help guide treatment.

Original languageEnglish (US)
JournalJCO Precision Oncology
Issue number2
DOIs
StatePublished - Jan 1 2018

Fingerprint

Hereditary Nonpolyposis Colorectal Neoplasms
Carcinoma
Mutation
Neoplasms
Germ-Line Mutation
DNA Repair
DNA Damage
Tobacco

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Donahue, T. F., Bagrodia, A., Audenet, F., Donoghue, M. T. A., Cha, E. K., Sfakianos, J. P., ... Bochner, B. H. (2018). Genomic characterization of upper-tract urothelial carcinoma in patients with Lynch syndrome. JCO Precision Oncology, (2). https://doi.org/10.1200/PO.17.00143

Genomic characterization of upper-tract urothelial carcinoma in patients with Lynch syndrome. / Donahue, Timothy F.; Bagrodia, Aditya; Audenet, François; Donoghue, Mark T.A.; Cha, Eugene K.; Sfakianos, John P.; Sperling, Dahlia; Al-Ahmadie, Hikmat; Clendenning, Mark; Rosty, Christophe; Buchanan, Daniel D.; Jenkins, Mark; Hopper, John; Winship, Ingrid; Templeton, Allyson S.; Walsh, Michael F.; Stadler, Zsofia K.; Iyer, Gopa; Taylor, Barry; Coleman, Jonathan; Lindor, Noralane M.; Solit, David B.; Bochner, Bernard H.

In: JCO Precision Oncology, No. 2, 01.01.2018.

Research output: Contribution to journalArticle

Donahue, TF, Bagrodia, A, Audenet, F, Donoghue, MTA, Cha, EK, Sfakianos, JP, Sperling, D, Al-Ahmadie, H, Clendenning, M, Rosty, C, Buchanan, DD, Jenkins, M, Hopper, J, Winship, I, Templeton, AS, Walsh, MF, Stadler, ZK, Iyer, G, Taylor, B, Coleman, J, Lindor, NM, Solit, DB & Bochner, BH 2018, 'Genomic characterization of upper-tract urothelial carcinoma in patients with Lynch syndrome', JCO Precision Oncology, no. 2. https://doi.org/10.1200/PO.17.00143
Donahue, Timothy F. ; Bagrodia, Aditya ; Audenet, François ; Donoghue, Mark T.A. ; Cha, Eugene K. ; Sfakianos, John P. ; Sperling, Dahlia ; Al-Ahmadie, Hikmat ; Clendenning, Mark ; Rosty, Christophe ; Buchanan, Daniel D. ; Jenkins, Mark ; Hopper, John ; Winship, Ingrid ; Templeton, Allyson S. ; Walsh, Michael F. ; Stadler, Zsofia K. ; Iyer, Gopa ; Taylor, Barry ; Coleman, Jonathan ; Lindor, Noralane M. ; Solit, David B. ; Bochner, Bernard H. / Genomic characterization of upper-tract urothelial carcinoma in patients with Lynch syndrome. In: JCO Precision Oncology. 2018 ; No. 2.
@article{64499a9652594b8f84a5e7ca49900cc8,
title = "Genomic characterization of upper-tract urothelial carcinoma in patients with Lynch syndrome",
abstract = "Purpose Patients with Lynch syndrome (LS) have a significantly increased risk of developing upper-tract urothelial carcinoma (UTUC). Here, we sought to identify differences in the patterns of mutational changes in LS-associated versus sporadic UTUCs. Patients and Methods We performed targeted sequencing of 17 UTUCs from patients with documented LS-associated germline mutations (LS-UTUCs) using the Memorial Sloan Kettering Integrated Molecular Profiling of Actionable Cancer Targets targeted exon capture assay and compared the results with those from a recently characterized cohort of 82 patients with sporadic UTUC. Results Patients with LS-UTUC were significantly younger, had had less exposure to tobacco, and more often presented with a ureteral primary site compared with patients with sporadic UTUC. The median number of mutations per tumor was significantly greater in LS-UTUC tumors than in tumors from the sporadic cohort (58; interquartile range [IQR], 47-101 v 6; IQR, 4-10; P < .001), as was the MSIsensor score (median, 25.1; IQR, 17.9-31.2 v 0.03; IQR, 0-0.44; P < .001). Differences in the genetic landscape were observed between sporadic and LS-associated tumors. Alterations in KMT2D, CREBBP, or ARID1A or in DNA damage response and repair genes were present at a significantly higher frequency in LS-UTUC. CIC, NOTCH1, NOTCH3, RB1, and CDKN1B alterations were almost exclusive to LS-UTUC. Although FGFR3 mutations were identified in both cohorts, the R248C hotspot mutation was highly enriched in LS-UTUC. Conclusion LS-and sporadic UTUCs have overlapping but distinct genetic signatures. LS-UTUC is associated with hypermutation and a significantly higher prevalence of FGFR3 R248C mutation. Prospective molecular characterization of patients to identify those with LS-UTUC may help guide treatment.",
author = "Donahue, {Timothy F.} and Aditya Bagrodia and Fran{\cc}ois Audenet and Donoghue, {Mark T.A.} and Cha, {Eugene K.} and Sfakianos, {John P.} and Dahlia Sperling and Hikmat Al-Ahmadie and Mark Clendenning and Christophe Rosty and Buchanan, {Daniel D.} and Mark Jenkins and John Hopper and Ingrid Winship and Templeton, {Allyson S.} and Walsh, {Michael F.} and Stadler, {Zsofia K.} and Gopa Iyer and Barry Taylor and Jonathan Coleman and Lindor, {Noralane M.} and Solit, {David B.} and Bochner, {Bernard H.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1200/PO.17.00143",
language = "English (US)",
journal = "JCO Precision Oncology",
issn = "2473-4284",
number = "2",

}

TY - JOUR

T1 - Genomic characterization of upper-tract urothelial carcinoma in patients with Lynch syndrome

AU - Donahue, Timothy F.

AU - Bagrodia, Aditya

AU - Audenet, François

AU - Donoghue, Mark T.A.

AU - Cha, Eugene K.

AU - Sfakianos, John P.

AU - Sperling, Dahlia

AU - Al-Ahmadie, Hikmat

AU - Clendenning, Mark

AU - Rosty, Christophe

AU - Buchanan, Daniel D.

AU - Jenkins, Mark

AU - Hopper, John

AU - Winship, Ingrid

AU - Templeton, Allyson S.

AU - Walsh, Michael F.

AU - Stadler, Zsofia K.

AU - Iyer, Gopa

AU - Taylor, Barry

AU - Coleman, Jonathan

AU - Lindor, Noralane M.

AU - Solit, David B.

AU - Bochner, Bernard H.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose Patients with Lynch syndrome (LS) have a significantly increased risk of developing upper-tract urothelial carcinoma (UTUC). Here, we sought to identify differences in the patterns of mutational changes in LS-associated versus sporadic UTUCs. Patients and Methods We performed targeted sequencing of 17 UTUCs from patients with documented LS-associated germline mutations (LS-UTUCs) using the Memorial Sloan Kettering Integrated Molecular Profiling of Actionable Cancer Targets targeted exon capture assay and compared the results with those from a recently characterized cohort of 82 patients with sporadic UTUC. Results Patients with LS-UTUC were significantly younger, had had less exposure to tobacco, and more often presented with a ureteral primary site compared with patients with sporadic UTUC. The median number of mutations per tumor was significantly greater in LS-UTUC tumors than in tumors from the sporadic cohort (58; interquartile range [IQR], 47-101 v 6; IQR, 4-10; P < .001), as was the MSIsensor score (median, 25.1; IQR, 17.9-31.2 v 0.03; IQR, 0-0.44; P < .001). Differences in the genetic landscape were observed between sporadic and LS-associated tumors. Alterations in KMT2D, CREBBP, or ARID1A or in DNA damage response and repair genes were present at a significantly higher frequency in LS-UTUC. CIC, NOTCH1, NOTCH3, RB1, and CDKN1B alterations were almost exclusive to LS-UTUC. Although FGFR3 mutations were identified in both cohorts, the R248C hotspot mutation was highly enriched in LS-UTUC. Conclusion LS-and sporadic UTUCs have overlapping but distinct genetic signatures. LS-UTUC is associated with hypermutation and a significantly higher prevalence of FGFR3 R248C mutation. Prospective molecular characterization of patients to identify those with LS-UTUC may help guide treatment.

AB - Purpose Patients with Lynch syndrome (LS) have a significantly increased risk of developing upper-tract urothelial carcinoma (UTUC). Here, we sought to identify differences in the patterns of mutational changes in LS-associated versus sporadic UTUCs. Patients and Methods We performed targeted sequencing of 17 UTUCs from patients with documented LS-associated germline mutations (LS-UTUCs) using the Memorial Sloan Kettering Integrated Molecular Profiling of Actionable Cancer Targets targeted exon capture assay and compared the results with those from a recently characterized cohort of 82 patients with sporadic UTUC. Results Patients with LS-UTUC were significantly younger, had had less exposure to tobacco, and more often presented with a ureteral primary site compared with patients with sporadic UTUC. The median number of mutations per tumor was significantly greater in LS-UTUC tumors than in tumors from the sporadic cohort (58; interquartile range [IQR], 47-101 v 6; IQR, 4-10; P < .001), as was the MSIsensor score (median, 25.1; IQR, 17.9-31.2 v 0.03; IQR, 0-0.44; P < .001). Differences in the genetic landscape were observed between sporadic and LS-associated tumors. Alterations in KMT2D, CREBBP, or ARID1A or in DNA damage response and repair genes were present at a significantly higher frequency in LS-UTUC. CIC, NOTCH1, NOTCH3, RB1, and CDKN1B alterations were almost exclusive to LS-UTUC. Although FGFR3 mutations were identified in both cohorts, the R248C hotspot mutation was highly enriched in LS-UTUC. Conclusion LS-and sporadic UTUCs have overlapping but distinct genetic signatures. LS-UTUC is associated with hypermutation and a significantly higher prevalence of FGFR3 R248C mutation. Prospective molecular characterization of patients to identify those with LS-UTUC may help guide treatment.

UR - http://www.scopus.com/inward/record.url?scp=85063942977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063942977&partnerID=8YFLogxK

U2 - 10.1200/PO.17.00143

DO - 10.1200/PO.17.00143

M3 - Article

AN - SCOPUS:85063942977

JO - JCO Precision Oncology

JF - JCO Precision Oncology

SN - 2473-4284

IS - 2

ER -